Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer... Show more
Get AI intraday signals
A.I. Advisor
published Earnings
JANX is expected to report earnings to rise 19.03% to -45 cents per share on August 12
Q2'25
Est.
$-0.45
Q1'25
Missed
by $0.01
Q4'24
Beat
by $0.07
Q3'24
Missed
by $0.18
Q2'24
Beat
by $0.20
The last earnings report on May 09 showed earnings per share of -37 cents, missing the estimate of -37 cents. With 333.39K shares outstanding, the current market capitalization sits at 1.46B.